Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search Materials

View All Favorites

A library of resources for the prevention,
management, and elimination of TB.

Showing 1 - 15 of 68 Results

Number of items to view
Filter Your Results

Filter Your Results

Title Year
MMWR: Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors

This guideline presents updated data about drug interactions between protease inhibitors and non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection together with rifamycins for treatment of TB.

2000
MMWR: Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations--United States, 2001

This report provides preliminary information about 21 cases of liver injury associated with rifampin-pyrazinamide (RIF-PZA) and the revised recommendations on selecting appropriate therapy for patients with latent TB infection and monitoring the use of RIF-PZA to treat infection.

2001
MMWR: Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000

This report discusses two cases of latent TB infection in which patients developed severe or fatal hepatitis associated with rifampin-pyrazinamide (RIF-PZA) treatment.

2001
INH: Standing Between You and Tuberculosis

This pamphlet discusses the use of the drug isoniazid (INH) to treat latent TB infection. It provides information on the length of treatment and side effects.

2001
What You Should Know About Taking Tuberculosis Medicines

This pamphlet discusses taking TB medicines, explains directly observed therapy, and the importance of taking all medications for the prescribed period of time.

2002
Frequently Asked Questions About the 4-Drug Fixed-dose Combination Tablet Recommended by the World Health Organization for Treating Tuberculosis

This booklet answers questions about the 4-drug fixed-dose combinations containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol that were added to the WHO Model List of Essential Drugs for the treatment of TB.

International Agencies
2002
Improving TB Drug Management: Accelerating DOTS Expansion

This book presents five papers that were used as background to a workshop on "Improving TB Drug Management: Accelerating DOTS Expansion" on June 2002, in Washington, DC. The papers address the weaknesses in drug management programs of certain countries and provide a framework for strengthening these programs through country-specific action plans.

International Agencies Managers and Supervisors Policy Makers
2002
Interventions for Tuberculosis Control and Elimination

This book discusses the medical treatments for TB as a means of prevention and elimination. It discusses typical first- and second-line treatments of TB, the use of prophylactic treatment in people exposed to TB, and the effectiveness of BCG vaccination in TB prevention.

2002
Revised Tuberculosis Treatment Guidelines-2003

This poster serves as a quick reference to the Revised Treatment of Tuberculosis Guidelines published in February 2003 by the American Thoracic Society, CDC, and the Infectious Disease Society of America. It contains information on treatment during the initial and continuation dosing phases, the range of total doses and the rating, information on PZA and ethambutol dosing, dosing recommendations for adult patients with reduced renal function as well as for those receiving hemodialysis, and information on how to monitor those patients.

2003
The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis

This pocket guide is intended to be a resource for physicians and other health care professionals who provide care and treatment to patients with MDR TB in DOTS-Plus projects.

2003
Treatment of Tuberculosis. Morbidity and Mortality Weekly Report Recommendations and Reports June 20 2003; 52(RR-11)1-77

This report presents recommendations for the treatment of tuberculosis.

2003
Treatment of Drug-Susceptible Tuberculosis Disease in HIV-Infected Persons

This fact sheet, available online or via fax only, discusses TB treatment options for persons with HIV/AIDS, including dosage recommendations for HIV-infected adults and children. It also discusses adverse reactions and special situations such as extrapulmonary TB, TB in HIV-infected pregnant women, and drug-resistant TB.

Infection Control and Occupational Health Workers
2003
The Current Anti-TB Drug Research and Development Pipeline

This report discusses compounds with potential for the treatment of TB and categorizes them into the discovery, preclinical, or clinical phases of development.

International Agencies
2003
Adherence to Long-Term Therapies: Evidence for Action

This report provides a critical review of what is known about adherence to long-term therapies.This is achieved by looking beyond individual diseases. A broad range of policy options emerges by including communicable diseases such as tuberculosis and human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), mental and neurological conditions such as depression and epilepsy, substance dependence (exemplified by smoking cessation), hypertension, asthma and palliative care for cancer.

Managers and Supervisors Policy Makers
2003
Treatment of Drug-Susceptible Tuberculosis Disease in Persons Not Infected with HIV

This fact sheet provides an overview of the treatment of drug-susceptible tuberculosis disease in persons not infected with HIV including the recommended drug regimens, case management, and follow-up evaluations.

Outreach Workers
2003